3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
15
Phase 2
6
Phase 1/2
2
Phase 4
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Head & Neck
2
Gastrointestinal
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Interventions
Azacitidine
41
Cytarabine
27
fludarabine phosphate
25
Cyclophosphamide
23
venetoclax
21
fludarabine
21
Peripheral Blood Stem Cell Transplantation
20
Mycophenolic Acid
17
Filgrastim
17
Decitabine
17
Tacrolimus
16
Whole-Body Irradiation
15
ruxolitinib
14
Cyclosporine
14
Busulfan
14
Melphalan
12
Methotrexate
10
Imatinib Mesylate
10
Stem Cell Transplantation
9
Antilymphocyte Serum
8
Alemtuzumab
8
nilotinib
7
decitabine and cedazuridine drug combination
7
Granulocyte Colony-Stimulating Factor
7
Rituximab
6
Injections
6
Idarubicin
6
Dasatinib
6
Clofarabine
6
AP 1903 reagent
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Hydroxyurea
×
Myeloid
×
Clear all
NCT06199557
2025-06-29
HUVAMER
Haukeland University Hospital
Phase 1/2
Recruiting
48 enrolled
NCT02480608
2015-06-24
CML2004
University of Leipzig
Phase 1/2
Completed
113 enrolled